Read + Share
. Correction: Risk of major adverse cardiovascular and venous thromboembolism
events in patients with rheumatoid arthritis exposed to JAK inhibitors versus
adalimumab: a nationwide cohort study. Ann Rheum Dis 2023;82:e222.
PMID: 37827705
|
 |
|
